ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science - 2017 (71 CME)

The ASAM 48th Annual Conference is the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine. The 2017 program includes more education offerings such as; seven concurrent sessions offerings at a time instead of six, three pre-conference courses instead of two.  There will also be three Plenary Sessions that include the popular Opening Plenary Session and Policy Plenary Session and new this year the National Perspectives Plenary Session moderated by the ASAM president with leaders from national federal agencies. There will be other exciting changes to provide learning in a more interactive, casual and fun environment. 

Learning Objectives:

At the conclusion of the conference, participants should be able to:

  • Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
  • Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
  • Analyze new research and science to develop practical applications for treatment or further research.
  • Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
  • Create a network of professionals or a set of resources that can be used to support the participant's practice.


  • Evaluation and Certificate - ASAM 48th Annual Conference

    Contains 2 Component(s), Medical Credits Offered

    CME Evaluation for the ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science

    Download the CME Tracking Sheet to assist with recording sessions attended at the conference. Complete the course evaluation first and then claim credits. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

  • Becoming Certified in Addiction Medicine through ABPM (1 CME)

    Contains 3 Component(s), Medical Credits Offered

    This session will review recent changes in the process of becoming board certified in addiction medicine.

    Starting in the fall of 2017, ABPM will offer physicians who are certified by a Member Board of the American Board of Medical Specialties (ABMS) the opportunity to become certified in the subspecialty of addiction medicine. The next five years following the date of the first exam is an optimum time for physicians to become Board Certified in addiction medicine. Physicians who are already certified by any of the 24 member Boards and have substantial experience in the field of addiction medicine are eligible to apply to take the examination. During the first five years the examination is given, individuals will NOT be required to complete an addiction medicine fellowship. After that, a one-year addiction medicine fellowship will be required. Upcoming Dates/Deadlines: 2017 Exam Applications Open: April 3 thru May 31, 2017. 2017 Exam Dates: October 16-28, 2017. For more info see ABPM booth in exhibit hall or www.theabpm.org.

    Marie A. Krousel-Wood

    MD, MSPH

    M.A. “Tonette” Krousel-Wood MD, MSPH, FACPM, FAHA is the Chair of the American Board of Preventive Medicine, Professor of Medicine in the Tulane School of Medicine, Professor of Epidemiology in the Tulane School of Public Health and Tropical Medicine, and serves in leadership roles including the Associate Provost for the Health Sciences at Tulane University.   

    She is actively engaged in NIH-funded clinical research and clinical trials focused on adherence to prescribed therapies, management of hypertension, health services and outcomes in patients with chronic cardiometabolic diseases.  In addition to her own research, she is committed to training the next generation of scientists and co-directs pre- and post-doctoral career development programs including serving as the Principal Investigator and Research Director for the NIH K12 Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) faculty career development award. She has presented her research findings at regional, national, and international meetings and has collectively published over 100 peer-reviewed articles, reports and book chapters. 
    She has held numerous leadership positions nationally including member and Chair of the National Institutes of Health Study Section, Health Services Organization and Delivery, President of the Southern Society for Clinical Investigation, President of Delta Omega national public health honorary society, member of the Board of Regents for the American College of Preventive Medicine, Chair and Director of the American Board of Preventive Medicine, and member of the National Institutes of Health Center for Scientific Review (NIH-CSR) Advisory Council. 

    Benson Munger

    PhD

    Benson Munger, PhD, is the Interim Executive Director of the American Board of Preventive Medicine.

    Michael F. Weaver

    MD, DFASAM

    Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine.  He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.

  • Improving Care with Triage, Assessment, Contingency Management & Monitoring Technology (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    This session will discuss what the clinical and resource benefits of adopting new technological innovations are and how data for all three approaches are informing clinical and policy interventions.

    Academic-entrepreneurial partnerships have generated computer-assisted innovations in: 1) comprehensive assessment/placement, 2) triage, and 3) contingency management. Data suggest improved outcomes and adoption. 1) Comprehensive assessment with CONTINUUM TM, the standard implementation of ASAM's Criteria, is a computer-guided, structured interview that operationalizes medical necessity criteria. CONTINUUM's decision engine can automate utilization review (UR). Through CMS's 1115 federal waiver program, county/state Medicaids are preparing to adopt it. In Los Angeles county (population: 10.1 million), piloting began in July 2016. UCLA is evaluating feasibility and impact on intakes and patient engagement. The web application captures: duration of assessment, completion rates, recommended placements, reasons for discrepant placements, patient characteristics, and satisfaction. The data may determine whether and how to proceed with county-wide adoption; how to streamline Medicaid and commercial insurance UR; determination of what levels of care, numbers of beds/slots are needed; and quality improvement. 2) Triage with the first derivative product of CONTINUUM, CONTINUUM Triage TM, emerged at the request of LA County and is also used in Massachusetts. This 20-question, computer-guided, structured interview (10-15 minutes, telephonic or in-person) determines the provisional level of care in which to complete the patient's CONTINUUM comprehensive assessment. SUD outcomes are improved when patients are provided the right care, at the right time, in the right setting, for the right duration - the goals of CONTINUUM Triage. Massachusetts also piloted both CONTINUUM and Triage, also for the CMS 1115 Waiver. Funded by the Governor's Opioid Working Group, Triage is being piloted in walk-in Opioid Urgent Care Centers in three high overdose cities. Both pilots analyze how often Triage's provisional recommendations are correctly matched to the final LOC recommendations of CONTINUUM. 3) Contingency management (CM), a high efficacy evidence-based practice, has been limited in its adoption by implementation burdens. CM restores healthy brain reward function with immediate small incentives that grow along a progressive reinforcement schedule. CM rewards healthy behaviors (e.g., sobriety) across all addictive substances, in many populations. DynamiCare Health, a fully-automated, scalable, patent-pending technology alleviates provider burdens by (1) ethically managing CM incentives, (2) automatically tracking/reporting data, and (3) using machine learning to provide impending relapse/dropout alerts for proactive intervention. Programs enroll new patients via the web. It provides an easy-to-use escrow account into which the patient deposits funds for CM reward incentives (e.g., from wages, welfare, family allowance, crowdfunding donations). The patient downloads the DynamiCare smartphone app for appointment tracking (via GPS), random/smart drug testing, and reward notifications. DynamiCare ships "selfie"-validating breathalyzers, CO detectors, and/or saliva drug test cups to the patient. Abstinence, medication adherence, or treatment attendance rewards transfer from the escrow account onto a debit card. Initial back-testing on spending data with machine learning has generated new, previously un-hypothesized independent variables in drug addiction, correctly predicting 70% of acute drop-outs. These technology developments offer nationwide implementation of data-driven care, service provision, payment reform, and outcomes improvement. Data for all three approaches are informing clinical and policy interventions.

    David Gastfriend

    MD, DFASAM

    David R. Gastfriend, MD, served on the faculty of Harvard Medical School for 25 years, most recently as Director of the Addiction Research Program at Massachusetts General Hospital (MGH). His studies of the Patient Placement Criteria published by the American Society of Addiction Medicine (ASAM) have been supported by the NIH's National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the U.S. Centers for Disease Control, U.S. state governments, managed care corporations, including Aetna Behavioral Healthcare, and foreign governments, including Belgium, Finland, Iceland, Israel, Norway, Switzerland, and the World Health Organization. The author of over 125 scientific publications, he has served on the Boards and Editorial Boards of a number of societies and journals, including ASAM and the International Society of Addiction Medicine (ISAM). He is co-editor of the leading book on treatment matching in the field, The ASAM Patient Placement Criteria for Substance-Related Disorders and editor of Addiction Treatment Matching. In addition to his role at RecoverySearch, Dr. Gastfriend is also Vice President for Scientific Communications at Alkermes, Inc. (NASDAQ: ALKS) where he is involved in research, education and scientific publication on extended-release naltrexone (VIVITROL®) and the company's efforts in the field of addiction treatment.

    Brian Hurley

    MD, MBA, DFASAM

    Dr. Brian Hurley is an addiction psychiatrist and Medical Director for Co-Occurring Disorder Services for the Los Angeles County Department of Mental Health (LACDMH), supporting the identification and management of co-occurring substance use among patients with mental illness served by LACDMH. He is an assistant professor of Addiction Medicine at UCLA. 

    Brian serves as the Treasurer and is a Distinguished Fellow of the American Society of Addiction Medicine. Brian joined ASAM in 2002 as a first year medical student, and has served on the ASAM Board of Directors in various capacities since 2003. Brian previously served as chair of ASAM’s Membership Committee and Physicians-in-Training Committee and is formerly ASAM’s alternate delegate to the American Medical Association. Brian additionally served on the EVP/CEO search committee in 2010 that led to Penny Mill’s selection as ASAM’s current EVP/CEO. He has additional served in various roles for the Massachusetts Society of Addiction Medicine, New York Society of Addiction Medicine, and California Society of Addiction Medicine.

    Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA), and was previously a Veterans Administration National Quality Scholar at the VA Greater Los Angeles Healthcare System. He completed residency training at the Massachusetts General Hospital and McLean Hospital, where he was Chief Resident in Addiction Psychiatry and addiction psychiatry fellowship training at Bellevue Hospital and the New York Veterans Administration. Brian is a graduate of the Keck School of Medicine and Marshall School of Business of the University of Southern California. He was a 2012 American College of Psychiatrists Laughlin fellow, a 2010-2013 American Psychiatric Association (APA) Public Psychiatry Fellow, and a 2015-2017 Group for Advancement of Psychiatry Fellow. Brian has previously served on the Board of Trustees of the APA.

    Eric E. Gastfriend

    MBA

    Eric Gastfriend is the Co-Founder and CEO of DynamiCare Health, a tech startup that is fighting substance addiction with evidence-based motivational tools. Previously, he was General Manager of Happy Cloud, a cloud gaming startup, where he oversaw software development and business development. Happy Cloud raised $7M in venture capital funding to make on-demand gaming possible for customers such as Warner Bros. Eric is currently managing DynamiCare Health’s strategy, operations, and fundraising. He earned his B.A. magna cum laude from Brown University and MBA from Harvard Business School. 

  • Addiction Medicine Fellowships: Training Clinical Experts, Faculty and Change Agents (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    With last year's formal recognition by the American Board of Medical Specialties and the Accreditation Council for Graduate Medical Education, opportunities are rapidly expanding for educational leaders in addiction medicine. This workshop will help participants who are interested in developing the new fellowship training programs that will build the national workforce of expert subspecialists and help integrate addiction medicine across the continuum of medical education. Based on a technical assistance model that has helped establish more than 40 fellowships since 2011, the session with include an exercise in step-by-step fellowship planning that can be used to start a subsequent accreditation application. Interested participants will be linked to ongoing support.

    Addiction medicine took a quantum leap forward in 2016 as the two major organizations overseeing medical specialty training and certification formally recognized the discipline as the nation's newest medical subspecialty. The historic decisions by the American Board of Medical Specialties (ABMS) and the Accreditation Council for Graduate Medical Education (ACGME) have now cleared the way for a dramatic growth in fellowship training programs. At the same time, collaboration between addiction medicine leaders and federal agencies has ignited efforts to integrate the teaching of the latest addiction science and evidence-based practices throughout the medical education continuum. This watershed moment presents a rare opportunity for those willing to assume leadership roles, and this workshop is designed to help them get started. The session will be modeled on the technical assistance program of The Addiction Medicine Foundation's National Center for Physician Training in Addiction Medicine. The strategy recognizes that addiction medicine fellowships are the necessary ingredient for producing an expert workforce of physician specialists, and for assuring that all physicians receive education and training in this essential competency. The starting point for any new fellowship is a champion to lead the effort, and the workshop, therefore, is designed for physicians who share this motivation. Physicians who are already teaching in a medical school or academic medical center are ideally placed, but fellowships may also be launched by community-based physicians whose prior experience with academic medicine is limited. This workshop will provide participants with an understanding of a fellowship program's key components, including personnel and curriculum. Utilizing a case study approach, it will also address areas such as developing the necessary institutional relationships to build a program and finding support to fuel its growth. The session will include an exercise in which participants will team up to complete a worksheet that can serve as the step-by-step blueprint for an actual accreditation application. Throughout the workshop, leaders from TAMF's National Center will interact with participants, drawing upon their experience assisting in the development of more than 40 addiction medicine fellowships since 2011. Ongoing support for interested participants will be arranged at the workshop's conclusion.

    Kevin Kunz

    MD, MPH, DFASAM

    Kevin Kunz, M.D., M.P.H., DFASAM is Executive Vice President of the American Board of Addiction Medicine (ABAM) and The ABAM Foundation. He served as ABAM President from 2008-2011, and previously served as an ASAM Director and Chair of the ASAM Chapters Council. He was Co-chair of the ASAM Medical Specialty Action Group, which recommended that an independent medical board be established to expand the formal involvement of the larger medical community and all of health care in the prevention and treatment of addiction.

    Andrew Danzo

    BA

    Mr. Danzo is Coordinator of the ABAM Foundation National Center for Physician Training in Addiction Medicine. He is also Associate Director of Program Development in the University at Buffalo Primary Care Research Institute and research instructor in the University at Buffalo Department of Family Medicine.

    Lon R. Hays

    MD, MBA, DFAPA, DFASAM

    Lon Roberts Hays, M.D., M.B.A. graduated from medical school at the University of Kentucky in 1982 then pursued residency training at the University of Kentucky, which he completed in 1986. At that time he joined the faculty in the Department of Psychiatry where he has served as Chair from 1998 to 2018, and is director of the Addiction Medicine Fellowship.  In addition to being Board Certified by the American Board of Psychiatry and Neurology, Dr. Hays also is certified by the American Board of Addiction Medicine and has Added Qualifications in both Addiction Psychiatry and Geriatric Psychiatry. He completed a Certificate of Medical Management in 1998 and went on to obtain his M.B.A. from the University of Kentucky Gatton School of Business in May 2001.  Dr. Hays is a Co-investigator on numerous grants involving drugs of abuse.  He is the Director of Area V of the American Academy of Addiction Psychiatry, President of the Addiction MedicineFoundation, a Distinguished Fellow of the American Psychiatric Association, and an elected member and Fellow of the American College of Psychiatrists."

    Alexander Y. Walley

    MD, MSc, FASAM

    Alexander Y. Walley, M.D., M.Sc., is an Associate Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Addiction Medicine Fellowship program and founded the Inpatient Addiction Consult Service at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients and methadone maintenance treatment. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. 

    Jeanette M. Tetrault

    MD, FACP, FASAM

    Dr. Tetrault’s scholarly work focuses on care of patients with addicition and the medical co-morbidities associated with substance use, mainly HIV and Hepatitis C. She is a diplomate of the American Board of Addiction Medicine. Dr. Tetrault is a physician providing primary care and buprenorphine/naloxone treatment at the Central Medical Unit of the APT Foundation, a multi-specialty addiction treatment facility, and is an attending physician at Yale New Haven Hospital (YNHH). She is the co-director of the Addiction Recovery Clinic in the Adult Primary Care Clinic at the St. Raphael's Campus of YNHH, which serves both a clinical care and a teaching mission. She was selected as a Macy Foundation Faculty Scholar in 2017. She is the Program Director for the Yale Addiction Medicine Fellowship Program and serves on the Board of Directors for The Addiction Medicine Foundation and the Addiction Medicine Fellowship Directors Association. She is a past-president of the New England Region of SGIM and co-chair of the Alcohol, Tobacco and Other Drug Use Interest Group for SGIM.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Opening Scientific Plenary & Distinguished Scientist Lecture (2 CME)

    Contains 3 Component(s), Medical Credits Offered

    The opening session will focus on the dawn of a new day in addiction medicine with an exciting lineup of ASAM award winners and luminaries in the field.

    Joseph Green A Beacon of Hope: There Are No Lost Causes As a spoken word artist, motivational speaker, and activist for the recovery community, Joseph Green uses poetry interwoven with storytelling to share his battle with addiction and subsequent recovery to deliver a message of inspiration to people who have chosen careers in prevention, intervention, and treatment. Using his own story, Joseph reconnects his audience to the source of their motivation, reminding them that, as important as it is to know what we are fighting against, it is more important to remember what we are fighting for Patrice Harris, MD, MA Sparking Change: The Providers' Role in Combatting the Opioid Crisis Prescription opioid misuse, overdose and death continues to be one of our nation's most complex and challenging public health threats. The American Medical Association and its partner organizations on the Task Force to Reduce Opioid Abuse are working to reverse the epidemic through physician leadership. These efforts include urging physicians to use Prescription Drug Monitoring Programs, enhancing physician education, increasing access to treatment for substance use disorders, promoting comprehensive pain care, including non-opioid and non-pharmacologic care, expanding access to the life-saving drug naloxone, and strengthening state Good Samaritan protections for bystanders who intervene to help overdose patients. As chair of the Task Force, and Board Chair at the AMA, Dr. Patrice Harris will examine key data and policy trends at state and national levels, discuss their effectiveness, and highlight specific efforts still needed to reverse the nation's opioid epidemic. Barbara Mason, PhD Shedding New Light on an Old Problem: Novel Treatments for Alcohol Use Disorder Recent advances in our understanding of the neurobiology of alcohol use disorder can serve as the basis for the development of novel pharmacotherapies. Specifically, the activation of brain stress systems in early abstinence offers pharmacological targets that can be restored to a homeostatic range of functioning and thereby support recovery. Results from clinical trials of novel medications in this domain will be presented, with implications for clinical practice. Vice Admiral Vivek H. Murthy, MD, MBA Facing Addiction: Shining a Spotlight on America's Most Pressing Public Health Issue In his 2016 breakthrough report, US Surgeon General Murthy showed the nation the ubiquitous reach of substance use and addiction in this country. Using staggering data, he defined the public health impact of substance misuse, but also illustrated the tremendous impact that resonates throughout every community. Vice Admiral Vivek H. Murthy will discuss what led to the release of this landmark publication, what the country's next steps will be, and why there is still reason to hope.

    Joseph Green

    Joseph Green is a spoken word artist, educator, and motivational speaker.  Over the past 10 years Joseph’s passion for youth development has led to him supporting young people in a multitude of facets.  He the co-founder and former Program Manager of poetryN.O.W., an after school creative writing program that worked with students throughout the DC metropolitan area.  After five years of successful programming, poetryN.O.W. was acquired by Split This Rock, a Washington DC based poetry and social justice organization, where Joseph now supervises youth programs in over 25 high schools.  In his work with poetryN.O.W. and Split This Rock, Joseph has also crafted an extensive creative writing curriculum now used in classrooms throughout the country.

    In his prevention work with high schooled aged youth, Joseph facilitates interactive workshops to create transformational original poems on the effects that substance abuse and addiction has had on their lives. By empowering students to speak truth to power, Joseph has provided opportunities for them to share their stories with policy makers at the White House for the US Office of National Drug Control Policy and the US Department of Education. In his role as Program Manager at the Mentor Foundation USA, Joseph led the effort to revamp the interactive drug prevention youth rally known as Shattering the Myths.  As part of this initiative, he also served as host for the three day program that included a full day of writing workshops and leadership training.
    2015 marked Joseph’s fifth return to Poetry Slam International’s national slam, this time as a representative of the DC Poetry Slam Team. He represented the Oneonta slam team in 2005 and 2006 as their Grand Slam Champion, Slam Richmond in 2009, and DC’s Beltway Poetry Slam team in 2011. He also represented DC in 2011 at the Individual Poetry Slam, ranking 16th in the world. As a solo artist, Joseph has performed, hosted, and featured at venues and schools throughout the United States, including the White House and Kennedy Center. He has over ten years experience as a professional spoken word artist and writer.
    Joseph believes in the power of using lived experiences to catalyze positive personal change, and often pulls from his own unique set of experiences to engage groups of all ages and backgrounds. In 2012 he started the interactive performance series, Dive Every Day Project, with the intent of opening dialogue around the topic of substance use disorder, addiction, and recovery. The Dive Every Day Project pulls from a catalog of original work dealing directly with these issues, drawing from personal and family experiences. Dive Every Day serves to be a tool of inspiration and guidance for all who encounter it and is a testament to self-forgiveness, redemption, and the irreplaceable role of love in the human revolution.

    Patrice A. Harris

    MD, MA

    Dr. Patrice Harris, a psychiatrist from Atlanta, is chair of the American Medical Association’s (AMA) Board of Trustees.

    Active in organized medicine her entire career, Dr. Harris has held many leadership positions at both the national and state level.  In addition to serving on the AMA’s Board of Trustees since 2011, Dr. Harris previously served as chair of the AMA’s Council on Legislation, and on the boards of the American Psychiatric Association and the Georgia Psychiatric Physicians Association.
    As past director of Health Services for Fulton County, Georgia, which includes Atlanta, Dr. Harris oversaw all county health-related programs and functions, and spearheaded the county’s efforts to integrate public health, behavioral health and primary care services.
    Governing themes in Dr. Harris’ professional life are a passion to improve the lives of children and service to others, and she has worked for children both clinically and in the advocacy arena.
    A key focus for Dr. Harris currently is developing solutions to end the nation’s opioid epidemic.  She is chair of the AMA’s Task Force to Reduce Opioid Abuse, which brings together specialty and state medical societies and other health care associations to move swiftly to implement best practices to combat the opioid epidemic and save lives.

    Barbara Mason

    PhD

    Barbara J. Mason, Ph.D. is the Pearson Family Professor, Director of the Pearson Center for Alcoholism and Addiction Research, Director of the Laboratory of Clinical Psychopharmacology, and Acting Chair of the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute, La Jolla, CA. Dr. Mason's work in medication development for the treatment of alcohol use disorders has been recognized with a MERIT Award from the National Institutes of Health (NIH), the Dean's Senior Clinical Research Award from the University of Miami School of Medicine, and the Andrew W. Mellon Foundation Teacher-Scientist Award from Cornell University Medical College. Dr. Mason conducted the seminal studies identifying nalmefene as having therapeutic potential for alcohol dependence; nalmefene (Selincro) has recently received regulatory approval for the treatment of alcohol dependence in the European Union. Dr. Mason also served as overall Principal Investigator for the US multicenter trial of acamprosate (Campral) for the treatment of alcohol dependence which was conducted in support of FDA approval. Dr. Mason has served on the National Advisory Councils of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Advisory Council of the National Institute on Drug Abuse (NIDA). Dr. Mason is an elected Fellow of the American College of Neuropsychopharmacology and has held multiple editorial positions, including serving as a current member of the editorial board for the Journal of Addiction Medicine. Dr. Mason holds the Pearson Family Chair, an endowed position in alcohol and addiction research at The Scripps Research Institute, and is currently conducting a program of NIH-funded research that includes human laboratory studies to screen medications for therapeutic potential for alcohol dependence and clinical trials to evaluate the safety and efficacy of novel medications for alcohol and cannabis dependence.

    Vivek H. Murthy

    Vice Admiral, MD, MBA

    Vice Admiral (VADM) Vivek H. Murthy, M.D., M.B.A., was nominated by President Barack Obama in November 2013 and confirmed on December 15, 2014 as the 19th United States Surgeon General. As America’s Doctor, Dr. Murthy is responsible for communicating the best available scientific information to the public regarding ways to improve personal health and the health of the nation. He also oversees the operations of the U.S. Public Health Service (USPHS) Commissioned Corps, comprised of approximately 6,700 uniformed health officers who serve in locations around the world to promote, protect, and advance the health and safety of our nation. 

    Dr. Murthy has devoted himself to improving public health through the lens of service, clinical care, research, education, and entrepreneurship. The son of immigrants from India, Dr. Murthy discovered a love for the art of healing early in his childhood while spending time in his father’s medical clinic in Miami, Florida. After attending Miami Palmetto Senior High School, he received his Bachelor’s degree from Harvard, and his M.D. and M.B.A. degrees from Yale. He completed his residency training at Brigham and Women’s Hospital and Harvard Medical School where he later joined the faculty as an internal medicine physician and instructor. As a clinician-educator, Dr. Murthy has cared for thousands of patients and trained hundreds of residents and medical students. He regards caring for patients as the greatest privilege of his life.  
    In addition to clinical practice, Dr. Murthy has two decades of experience and perspective improving health in communities across the country and around the world. He co-founded VISIONS, an HIV/AIDS education program in India and the United States, which he led for eight years. As its president, he established ten chapters with hundreds of volunteers in both countries and grew the organization’s education programs to reach more than 45,000 youth. Dr. Murthy also co-founded the Swasthya project (“health and wellbeing” in Sanskrit), a community health partnership in rural India, to train women to be health providers and educators. During his five-year tenure with the organization, he established seed funding and helped expand research and direct care programs that reached tens of thousands of rural residents.
    As a research scientist, Dr. Murthy has conducted laboratory research on vaccine development and studied the participation of women and minorities in clinical trials. His research findings have been published in Science, the Journal of the American Medical Association, and the Journal of the National Cancer Institute. Dr. Murthy is also a healthcare entrepreneur and innovator. He co-founded and chaired a successful software technology company, TrialNetworks, which improves research collaboration and enhances the efficiency of clinical trials around the world. In seven years, Dr. Murthy and his team took the company from conception to an international enterprise that powers dozens of clinical trials for over 50,000 patients in more than 75 countries. Dr. Murthy has also served as the president of Doctors for America, a non-profit organization with more than 16,000 physicians and medical students in all 50 states who work with patients and policymakers to build a high quality, affordable health system for all.
    Seen by many as a proven leader who can use 21st century approaches and technology to modernize the role of Surgeon General, Dr. Murthy will focus his efforts on building cross-sector partnerships in communities to address the epidemics of obesity and tobacco-related disease, to reduce the stigma associated with mental illness, to improve vaccination rates, and to make prevention and health promotion the backbone of our communities. Dr. Murthy firmly believes that our nation's greatest strength has always come from its people. Improving the health of our people means strengthening our communities and our country. That will be Dr. Murthy’s highest priority as Surgeon General. 

  • Addiction 60/60: All of Addiction Medicine in 60 Slides and 60 Minutes (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    This session offers an ultra-fast-paced, “state-of-the-art” review of 2017 Addiction Medicine in the context of our current understanding of the addictive process. We will review how current neurobiology approaches craving and control, and how these novel concepts inform our treatment options, both pharmacological and psychosocial.

    Addiction specialists these days do much more than treat patients. Educating people about addiction and helping them understand the disease from a medical perspective is a ubiquitous request. From giving a Grand Rounds presentation to seasoned attending physicians to training hospital staff through in-service programs to responding to the media, we are often called on to talk about addiction and its treatments. In this workshop, we will attempt to refine a one-hour PowerPoint lecture that covers the essentials of Addiction Medicine in 2017. We will strictly use 60 slides with no more than 60 words per slide to deliver the lecture. The first part, the Fundamentals of Addiction Medicine will cover (1) the Neurobiology of Addiction; (2) Alcohol; (3) Sedatives; (4) Opioids; (5) Stimulants; (6) Nicotine; (7) Cannabis; (8) Dissociatives, Hallucinogens, and Steroids; and (9) the Behavioral Addictions. The second part, Assessments and Treatments will address (1) the Epidemiology of Addiction; (2) Public Policy; (3) Screening, Brief Intervention, and Referral to Treatment (SBIRT), ASAM Patient Placement Criteria (PPC), and other Assessment Tools; (4) Toxicology Examinations; (5) 12-Step Programs; (6) Cognitive Behavior Therapy; (7) Motivational Interviewing; (8) Medical Co-Morbidities; and (9) Psychiatric Co-Morbidities. Finally, the third part, Special Populations and Topics will look into (1) Pain and Addiction; (2) Maternal/Child Issues; (3) Adolescents; (4) the Elderly; (5) Impaired Professionals; and (6) the Future of Addiction Medicine. This 24-part review of our field can also serve as a basic template for the development of full-day or multiple-day courses in Addiction Medicine. During the second hour of the workshop, the presenters will invite participants to critique the presentation; change, add, or delete topics and slides; and discuss the usefulness of such an admittedly ambitious undertaking. This is the second time that we will try this approach-- the first time we attempted the 60/60 was at the 2013 ASAM Med-Sci Conference in Chicago. We have refined the presentation since then, based on feedback we have received from students, trainees, and fellow addiction specialists.

    Petros Levounis

    MD, MA, DFASAM

    Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he received an MA degree in sociology from Stanford before moving to New York City where he trained in psychiatry at Columbia University. He graduated from Columbia receiving the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University. From 2002 to 2013, he served as director of the Addiction Institute of New York.
    Dr. Levounis has written numerous articles and monographs; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by all major television networks. Dr. Levounis serves on the Board of Directors of the American Society of Addiction Medicine (ASAM) and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association. Dr. Levounis is a Betty Ford Scholar, a recipient of a U.S. State Department Speaker and Specialist Award, a distinguished fellow of the APA and ASAM, and an honorary member of the World Psychiatric Association. 

    Dr. Levounis has published thirteen books including the self-help paperback “Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself,” the textbook of “Substance Dependence and Co-Occurring Psychiatric Disorders,” “The Behavioral Addictions,” “Motivational Interviewing for Clinical Practice,” “Becoming Mindful,” and the “Office-Based Buprenorphine Treatment of Opioid Use Disorder,” now in its second edition. His books have been translated into German, Hungarian, Japanese, Portuguese, and Spanish. 

    Dr. Levounis is married to actor Lukas Hassel and lives in New York City.

  • Engaging Healthcare Practitioners to Address the Opioid Crisis (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    This session will review: Survey data of NPs interest in treating OUD and obtaining a waiver to prescribe MATs; Potential barriers for NPs related to prescribing MATs and Current status of number of NPs that have registered for the required 24 hours of education for waiver application.

    Despite substantial efforts to encourage adoption of evidence-based practices, the use of medications to treat substance use disorders is still low in both primary care and specialty addiction treatment settings. In this presentation the status of efforts to implement buprenorphine prescribing in primary care and other settings will be described. Barriers to treatment for opioid use disorders and potential strategies to address them such as collaborative care models will be discussed. Successful strategies and lessons learned from efforts to encourage the provision of buprenorphine in specialty and general medical settings will be identified in order to inform future efforts to expand access to medication for opioid use disorder. The Massachusetts Collaborative Care Model for the delivery of opioid agonist therapy with buprenorphine, in which nurses working with physicians play a central role in the evaluation and monitoring of patients, holds promise for the effective expansion of treatment for opioid use disorders. The Massachusetts Bureau of Substance Abuse Services (BSAS) initiative to implement the office-based opioid treatment with buprenorphine (OBOT-B) collaborative care model in fourteen community health centers (CHCs) will be described. With the passage of the Comprehensive Addiction and Recovery Act of 2016 (CARA), significant changes to federal policies will ultimately increase states' capacity to provide medication-assisted treatment. Representatives from the American Association of Nurse Practitioners (AANP), the American Academy of Physician Assistants (AAPA), and the American Society of Addiction Medicine (ASAM) Medical Education Council will describe stakeholders' interest in providing treatment for substance use disorders and identify needs of their constituencies. Each speaker will provide recommendations regarding the messaging needed to address stigma and to engage healthcare professionals. Speakers will also identify potential pitfalls or barriers to consider in efforts to encourage healthcare practitioners to identify and treat substance use disorders. After brief didactic presentations, a panel discussion with addiction medicine experts and representatives from nursing, NP, and PA communities will be held. Through interactive discussion speakers will address questions most relevant to attendees and discuss factors influencing the engagement of healthcare practitioners in local settings to increase access to appropriate, evidence-based treatments for opioid use disorder across the country.

    Kristen Huntley

    PhD

    Kristen Huntley, Ph.D., is a Health Scientist Administrator at the National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Center for Clinical Trials Network (CCTN) where she oversees research studying the effectiveness and implementation of interventions for the treatment of substance use disorders in multi-site, nationwide studies that enroll large samples of diverse participants in general medical settings and community-based treatment programs. Dr. Huntley also manages activities conducted through NIDA’s Blending Initiative. This initiative supports collaboration between clinicians, scientists, and experienced educators to facilitate the adoption of evidence-based practices in front-line clinical settings. During her tenure at NIH Dr. Huntley has served as a Scientific Review Officer at NIDA and as a Program Director at the National Center for Complementary and Integrative Health (NCCIH) where she administered a portfolio of pain management research grants and led efforts to build collaborations with other federal agencies to encourage research on the use of integrative models of care in military and veteran populations. Prior to working at NIH, Dr. Huntley was on the faculty at Case Western Reserve University School of Medicine, a project director at a research and consulting firm, and has worked in a variety of healthcare settings. Dr. Huntley has a Ph.D. in clinical psychology and has over 20 years of experience in academic, research, and clinical settings.

    Jeffrey Samet

    MD, MA, MPH

    Dr. Samet is a graduate of Brandeis University and Baylor College of Medicine. He trained in Internal Medicine at Boston City Hospital, Boston University School of Medicine (BUSM), and in a research fellowship at the Massachusetts General Hospital. He has been a primary care physician in Boston since 1983. Dr. Samet is a Professor of Medicine at Boston University School of Medicine and Professor of Community Health Sciences at the Boston University School of Public Health. In 2002, he became the Chief of General Internal Medicine at BUSM/Boston Medical Center and Vice Chair for Public Health in the Department of Medicine. Dr. Samet has a longstanding commitment to educating physicians about substance use disorders. From 1995-2012 he served as Medical Director of Substance Abuse Prevention and Treatment Services for the Boston Public Health Commission. He was President of the Association of Medical Education and Research in Substance Abuse (1999- 2001), co-chair of the Substance Abuse Task Force of the Society of General Internal Medicine (1992-2002), and a member of the Institute of Medicine Committee on Addressing the Quality Chasm in Mental Health and Addictive Disorders. Dr. Samet chaired the ASAM Medical-Scientific Annual Conference Program Committee 2004-2010 and 2012-2013 he served as President of the American Board of Addiction Medicine (ABAM) and the ABAM Foundation.

    Colleen LaBelle

    BSN, RN-BC, CARN

    Colleen LaBelle has certifications in addiction nursing and HIV with over 20 years of clinical experience in HIV and addiction, and co-authored a publication in the Journal of General Internal Medicine, “Treating Homeless Opioid Dependent Patients with Buprenorphine in an Office-based Setting." She was instrumental in the start up of the OBOT Program in the BMC Primary Care Clinic, which manages over 450 active patients with buprenorphine. This program provides buprenorphine treatment for patients in primary care, homeless, HIV, Family Medicine, OB, and support to the affiliated community health centers. She is the program director of the STATE OBOT B (State Technical Assistance, Treatment Expansion of Buprenorphine) working with 14 community health centers implementing a nurse care manager model for the expansion of buprenorphine. Since 2003, Ms. LaBelle has served as Faculty for the buprenorphine certification course of the American Society of Addiction Medicine. She frequently gives presentations on buprenorphine and provides consultation and technical assistance on- and offsite and by telephone. She oversees the MDPH buprenorphine list-serve and provides liaison for MDPH supported buprenorphine training, education and start-up in Massachusetts. She speaks on a local and national level, and has been a part of the SAMHSA Summit on Buprenorphine. Ms. LaBelle has served as a member of the Scientific Study (Study Section) Review Committee for the National Institute on Drug Abuse. Since 2004, she has served on the National Advisory Committee on Buprenorphine for the Health Resources and Services Administration and participated in professional editing of TAP 30 Technical Assistance Publication for Nurses with SAMHSA, 2009. Co-author : Five Year Experience with Collaborative Care of Opioid Addicted Patients using Buprenorphine in Primary Care, published Archives of Internal Medicine. In May 2011 she was the recipient of Individual Leadership Award, for Innovation In Health Care from MA Bureau of Substance Abuse Services as well as a NIATX award recipient 2011 Innovations in Behavioral Health Services award for Process Improvements. She is a board member of the Addiction Nurses Certification Board, and recently started a MA Chapter for addiction nurses.

    Andrew Saxon

    MD, FASAM

    Andrew J. Saxon, M.D. Professor, Department of Psychiatry and Behavioral Sciences, University of Washington Director, Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System Director, Addiction Psychiatry Residency Program, University of Washington Preceding his entry into psychiatry, Dr. Saxon completed an internal medicine internship and worked for 4 years as an emergency room physician. Subsequent to his general psychiatry residency at the University of Washington, Dr. Saxon has more than a quarter century of experience as a clinical and research addiction psychiatrist. Dr. Saxon is board certified with added qualifications in addiction psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, Drug and Alcohol Dependence and General Hospital Psychiatry. Dr. Saxon's current research work is supported by the VA, the Department of Defense, and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, cocaine, tobacco, and opioid use disorders as well work in co-occurrence of substance use disorders and posttraumatic stress disorder and on reducing homelessness.

    Marie-Michele Leger

    MPH, PA-C

    Ms. Léger a PA for 33 years is director, clinical education at AAPA.  She obtained a  Bachelor’s of Science, Physician Assistant Program, George Washington University (GWU), Washington DC in 1983 and completed her Master in Public Health, (International Health, Concentration: Health Promotion/Disease Prevention), from GWU in 1996.  
    She monitors, advises AAPA’s leadership on issues in clinical medicine, public health, coordinates activities that relates to continuous professional development, translate best available evidence which leads to PA practice improvement.   Ms.  Léger is the AAPA’s liaison to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP).  She has published extensively; written editorials on raising the awareness of emergency preparedness and raising the rate of adult immunization.  Ms. Léger has given presentations in the United States and internationally addressing the PA profession, disparity in healthcare, immunization, and other infectious disease topics.  Ms. Léger retains a faculty appointment at the George Washington University School of Medicine and Health Sciences and at the Shenandoah Physician Assistant Program.

    Anne Norman

    DNP, APRN, FNP-C, FAANP

    Dr. Anne Norman is a Family Nurse Practitioner (FNP) and the Vice President of Education and Accreditation at the American Association of Nurse Practitioners (AANP).  She received her Master of Science in Nursing at the University of Alabama at Huntsville in 1994 and her Doctor of Nursing Practice at the University of Alabama at Birmingham in 2010.  Dr. Norman has practiced in primary care and held leadership positions in various settings including: a multiple disciplinary medical school health center, rural health, college health, retail health and workplace/occupational health.  At AANP, she serves as the primary organizational resource on continuing education (CE) and education-related standards, recommendations, and requirements.  Her responsibilities include directing the grant, education, and accreditation activities of the association by overseeing and guiding the planning, development, and implementation of educational activities and programs to meet strategic goals.

    Daniel P. Alford

    MD, MPH, FACP, DFASAM

    Dr. Daniel P. Alford is an Associate Professor of Medicine, Assistant Dean of CME and Director of the Safe and Competent Opioid Prescribing Education (SCOPE of Pain) program at Boston University School of Medicine. He is a diplomate in Addiction Medicine by the American Board of Addiction Medicine (ABAM).

    He is director of the Clinical Addiction Research and Education Unit medical director of the Office-Based Opioid Treatment (OBOT) program and of the Massachusetts Screening, Brief Intervention, Referral to Treatment Training and Technical Assistance (MASBIRT TTA) program and former program director for the Addiction Medicine Fellowship program at Boston Medical Center (BMC). Since 2001 he has served as the course director of the Chief Resident Immersion Training (CRIT) Program in Addiction Medicine: Improving Clinical and Teaching Skills for Generalists funded by NIDA. He is president of the Association for Medical Education and Research in Substance Abuse (AMERSA). In 2011, he was recognized as a Champion of Change by the White House. In 2014 he received the Health Education Award from the American Medical Association.

  • Interventional Pain Management: A Pain Control Strategy for the Patient in Treatment (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    The presentation will include vignettes of treatment options for problems that are commonly seen in both the pain management office, and the addiction treatment setting. A brief overview of the type of available procedures, and their risks and options will be discussed. We will then allow time for questions. Drs. Hansen and Silverman are both active and Board members of the American Society of Interventional Pain Physicians, which is a group of physicians and extended care providers that train and provide resources to treat our patients in pain. Their experience in pain medicine and addiction medicine allow them to present a perspective that is unique to the complex patient in treatment and pain.

    The patient in treatment presents in many complex forms, often with a complaint of pain. The pain may have been the origin of the addiction, or might be a process that shares a relationship to the purpose driven seeking of controlled substances, particularly opioids. Pain and addiction are often seen together, and an item of significant risk in both the pain management population, and the substance abuse arena. The overlap of symptoms is common. The practitioner often searches for alternative care strategies, to minimize opioid load, and improve function and quality of life. It is the purpose of this presentation to demonstrate a very powerful therapeutic pathway, with emphasis on pain control, without escalating controlled substances. Many examples of success have eliminated controlled substances and reduced pain. These interventional techniques that are performed are both diagnostic and therapeutic, and assist in an overall strategy of independence from opioid management of pain. Discussed will be spinal procedures, musculoskeletal procedures, and vignettes apply these therapies to a practical world. Interventional procedures are often very cost effective, that enhance positive benchmarks in a timely fashion. Interventional pain medicine is the application of target specific medication therapy to a pain generator. Interventional pain medicine also includes advanced technology such as spinal cord stimulation, and radiofrequency ablation that addresses pain refractory to common therapeutic approaches. An interventional pain physician might come from neurology, anesthesiology, or physical medicine and rehab, as a primary specialty, with added training and credentials to demonstrate proficiency. In proper hands these procedures are safe, cost effective, and afford very specific populations control of one of the most common complaints in American medicine, pain. As new technologies emerge, an exciting emergence of cutting edge thought, even rejuvenative medicine can return an individual to an active and functioning vital member of society. The fragile pain population of those in treatment for addiction can ill afford the setbacks of those suffering from pain with no hope. These techniques and the promise of new advances in development, lend to an important academic discussion that is timely for those who treat addiction.

    Sanford M. Silverman

    MD

    Sanford M. Silverman, MD, is in private practice; Institute of Pain Management, Pompano Beach, Florida. He is board certified in anesthesiology, with added qualifications in Pain Management from the American Board of Anesthesiology and a Diplomate in Pain Medicine from the American Board of Pain Medicine.  He is also a Diplomate in Addiction Medicine from the American Board of Addiction Medicine.  His practice consists of interventional and medical treatment of chronic pain, the treatment of various addictive disorders, and currently has an interest in treating complex chronic pain, addiction, and hyperalgesia.

    After receiving his bachelor and master degrees in Chemical Engineering from Tufts University in Medford, Massachusetts, Dr. Silverman earned his medical degree from New York Medical College. He then entered active duty military service with the US Army and completed a transitional internship at Letterman Army Medical Center in San Francisco, California. He then completed a residency in anesthesiology at Brooke Army Medical Center in San Antonio, Texas.  
    After completing his training, he served as Major, US Army and Chief of the Anesthesia and Operative Service at William Beaumont Army Medical Center in El Paso, Texas where he also was also the director of the pain clinic. 
    Dr. Silverman is the director of the Controlled Substance Management course, for the American Society of Interventional Physicians which is a core requirement for board certification in Interventional Pain Medicine.  In 2016 he co-authored a text book titled: Controlled Substance Management in Chronic Pain; A Balanced Approach. 
    Dr. Silverman is also an Affiliate Assistant Professor of Clinical Biomedical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Florida Atlantic University,  Boca Raton, FL., 
     Dr. Silverman served on the stakeholder committee of the CDC Opioid Guidelines, representing ASIPP. 

    Hans C. Hansen

    MD

    Hans C. Hansen, MD 

    President-Elect, ASIPP 
    Executive Director, NCSIPP 
    Medical Director, 
    The Pain Relief Centers, PA  
    Conover, North Carolina 

    Hans C. Hansen, M.D. was raised in Denver, Colorado, where he received his Doctorate in Medicine from the University of Colorado Health Sciences Center.  He trained and completed his residency in anesthesiology and a subspecialty year in chronic pain management at Yale University School of Medicine.  Dr. Hansen is board certified and re-certified by the American Board of Pain Medicine, completed testing for the World Institute of Pain, assisted in administration of the second FIPP exam, and is credentialed with the American Board of Interventional Pain Physicians (ABIPP).  He is on the Board of Directors, a past president, and current president-elect of American Society of Interventional Pain Physicians (ASIPP). He is board certified in Addiction Medicine. Dr. Hansen’s practice is located in Central Piedmont North Carolina. 

  • Role of Pediatricians in the Prevention, Assessment &Treatment of Substance Use Disorders (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Nearly all substance use disorders (SUDs) can be traced to adolescence, when the vulnerable adolescent brain is first exposed to psychoactive substances. With a backdrop in brain biology, this presentation will present the clinical and policy implications for managing the highly prevalent chronic and serious problem of SUDs in this high-risk population. We will review the AAP guidance for pediatricians and discuss strategies for providing SBIRT (Screening, Brief Intervention and Referral to Treatment) in primary care clinical settings.

    Nearly all substance use disorders (SUDs) can be traced to adolescence, when the vulnerable adolescent brain is first exposed to psychoactive substances. Most adolescents have annual pediatric visits throughout their youth, presenting an important opportunity for pediatricians and adolescent medicine physicians to deliver prevention and early intervention messages in an effort to reduce substance use and SUDs. In June 2016, the American Academy of Pediatrics (AAP) Committee on Substance Use and Prevention released a clinical report "Substance Use Screening, Brief Intervention, and Referral to Treatment" to guide physicians in implementing substance use prevention, detection, assessment and intervention in settings in which adolescent receive health care. In this report, the AAP presents a new vision for physicians to routinely counsel their young patients about the medical impacts of substance use, stressing the importance of not using any alcohol, tobacco, marijuana or other drugs for reasons of health. This contrasts strongly with earlier more passive strategies for pediatricians. New analyses of data from the National Survey on Drug Use and Health (NSDUH) show the use of alcohol, tobacco and marijuana is closely linked among young people. Use of one of these three substances significantly increases the likelihood of using the other two. Further, the no-use goal for health can be achieved as evidenced by data from the Monitoring the Future study showing a dramatically increasing percentage of young people refraining from using alcohol, cigarettes, marijuana or other drugs. Screening patients for substance use is only the first step. The goals of the brief interventions which follow screening range from providing positive reinforcement and prevention messages for patients who abstain from substance use, to encouraging patients with moderate and more severe substance use disorders to reduce their use and accept a referral to treatment with follow-up to ensure compliance with treatment. The ultimate health goal for adolescents is no use of any substance for health. With a backdrop in brain biology, this presentation will present the clinical and policy implications for managing the highly prevalent chronic and serious problem of substance use disorders in this high-risk population. We will review the AAP guidance for pediatricians and discuss strategies for providing SBIRT (Screening, Brief Intervention and Referral to Treatment) in primary care clinical settings.

    Robert L. DuPont

    MD, DFASAM

    For more than 40 years, Robert L. DuPont, M.D. has been a leader in drug abuse prevention and treatment. He served as the first Director of the National Institute on Drug Abuse (1973-1978) and as the second White House Drug Chief (1973-1977). From 1968-1970 he was Director of Community Services for the District of Columbia Department of Corrections, heading parole and half-way house services. From 1970-1973, he served as Administrator of the District of Columbia Narcotics Treatment Administration. Following this distinguished public career, in 1978 Dr. DuPont became the founding president of the Institute for Behavior and Health, Inc., a non-profit organization that identifies and promotes new ideas to reduce illegal drug use. He has been Clinical Professor of Psychiatry at the Georgetown University School of Medicine since 1980. 

    A graduate of Emory University, Dr. DuPont received an M.D. degree in 1963 from the Harvard Medical School. He completed his psychiatric training at Harvard and the National Institutes of Health in Bethesda, Maryland. 

    Dr. DuPont is a Life Fellow of the American Society of Addiction Medicine. His activities in ASAM include chairing the forensic science committee from 1995 to 2004, and serving as Co-Chair of the two White Paper writing committees that produced The Role of the Physician in “Medical” Marijuana in 2010 and State-Level Proposals to Legalize Marijuana in 2012. He served as Chair of the writing committee that produced Drug Testing: A White Paper of the American Society of Addiction Medicine in 2013. He is also a Life Fellow of the American Psychiatric Association and was chairman of the Drug Dependence Section of the World Psychiatric Association from 1974 to 1979. In 1989 he became a founding member of the Medical Review Officer Committee of ASAM."

    Sharon Levy

    MD, MPH

    Sharon Levy, MD, MPH, is a board certified Developmental-Behavioral Pediatrician and an Assistant Professor of Pediatrics at Harvard Medical School; she also has a Master's degree from the Harvard School of Public Health. She is the Director of the Adolescent Substance Abuse Program in the Divi-sion of Developmental Medicine at Boston Children's Hospital where she has evaluated and treated hundreds of adolescents with substance use disorders. She has published extensively on the outpatient management of substance use disorders in adolescents, including screening and brief advice in primary care, the use of drug testing and the outpatient management of opioid de-pendent adolescents. She is the PI of the SAMHSA-funded medical residen-cy SBIRT project at Children's Hospital Boston and an NIAAA-funded study validating the youth alcohol screening tool in a population of youth with chronic medial illness. Dr. Levy currently serves as the chair of the American Academy of Pediatrics Committee on Substance Abuse.

  • Designing Memorable Workshops: A Workshop for Presenters and Teachers of Addiction Medicine (1 CME)

    Contains 3 Component(s), Medical Credits Offered

    This session will use a combination of brief didactic teaching and a variety of interactive and participatory methods. We will introduce learners to the steps of workshop design and evaluation.

    People remember about 20% of what they hear, 30% of what they see and 50% of what they see and hear. (Labonte, 1972) Most importantly, people remember how you made them feel. Therefore, when we teach we need to make it memorable by making the learning transformational. We need to create learning environments where in addition to cognitive learning, we promote affective and psychomotor learning ( Bloom's taxonomy, 1964). Workshops are brief small group learning activities which allow learners the opportunity to participate in problem solving to facilitate knowledge acquisition, attitudinal change or skill development. When properly designed based on adult and experiential learning principles it can be a time and cost efficient method of instruction. Moreover, it makes learning fun! This facilitated small group session will use a combination of brief didactic teaching and a variety of interactive and participatory methods. We will introduce learners to the steps of workshop design and evaluation. In addition we will have small groups co-create the development of an interactive exercise based on the competencies for Addiction Medicine. Techniques to enhance interaction and audience participation such as "pair and share" will be practiced. The workshop will conclude with a large group debrief and commitment by participants to submit a workshop for consideration at the next ASAM annual conference.

    Peter Selby

    MBBS, CCFP, FCFP, DFASAM

    Peter Selby MD is the Director of Medical Education and a Clinician Scientist at the Centre for Addiction and Mental Health. He is a Professor in the Departments of Family and Community Medicine, Psychiatry, and the Dalla Lana School of Public Health at the University of Toronto. He is also a Clinician Scientist in the Department of Family and Community Medicine. Dr. Selby is the Executive Director and creator of the TEACH project; a continuing education certificate program in Applied Counselling for Health with a focus on smoking cessation, through the University of Toronto. Dr. Selby’s research, as a Principal Investigator at the Ontario Tobacco Research Unit, includes smoking cessation especially in smokers with co-morbid conditions. As the Principal Investigator of the STOP Study, he investigates the effectiveness of NRT and counselling in different types of intervention settings. He is also the PI of CANADAPTT- a unique Canadian Smoking Cessation Guideline development and dissemination project. Dr. Selby also continues his clinical research with pregnant women who use substances and is the PI of a knowledge translation program (PREGNETS) to increase the adoption of evidence-based interventions with pregnant smokers. 

    He has received grant funding totaling over 80 million dollars from CIHR, NIH, and Ministry of Health and has published 130 peer reviewed publications. He has published 5 books (including 4 edited), is the author of 30 book chapters, and 32 research reports prepared for the government. He is the Co-Chair for the Ministry of Health Cessation Task force and the Chair of the Canadian Centre on Substance Abuse National Task Force on Treatment for Prescription Drug Misuse. Dr. Selby mentors Fellows in Addiction Medicine and Addiction Psychiatry, junior investigators and medical students. Dr. Selby a sought after speaker for various topics including addictive disorders, motivational interviewing, and health behavior change.

    Miriam S. Komaromy

    MD, FACP, DFASAM

    Dr. Komaromy is an Associate Professor of Medicine and Associate Director of the ECHO Institute (echo.unm.edu), which is a program based at the University of New Mexico Health Sciences Center that is aimed at expanding access to treatment for traditionally underserved populations. She is Director for the Integrated Addictions and Psychiatry teleECHO program, which engages and supports primary care teams in treating addiction and behavioral health disorders. Through this program she has trained more than 500 physicians to provide buprenorphine treatment for opioid use disorder. She is board certified in Addiction Medicine through the American Society of Addiction Medicine. She serves on several national committees focused on addiction medicine.. She practices addiction medicine in a primary care outpatient clinic setting, and is a newly elected Board Member for the American Society of Addiction Medicine (ASAM). She has served as medical director for the NM State Addiction Treatment Hospital. She lectures nationally on clinical and health policy issues related to integration of addiction treatment into the primary care setting, and on the use of the ECHO model to train primary care providers to treat common, complex diseases such as behavioral health and substance use disorders. 

    Michael Fingerhood

    MD, FACP

    Dr. Michael Fingerhood is an Associate Professor of Medicine at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance abuse treatment with primary medical care, including care for HIV and hepatitis C.

Accreditation Council for Continuing Medical Education (ACCME)

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The ASAM 48th Annual Conference - Innovations in Addiction Medicine and Science

The American Society of Addiction Medicine designates this enduring material for a maximum of 71 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABAM Transitional Maintenance of Certification (Tmoc)

This course has been approved by the American Board of Addiction Medicine (ABAM).  Physicians enrolled in the ABAM Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 71 AMA PRA Category 1 Credit(s)™ for completing the The ASAM 48th Annual Conference – Innovations in Addiction Medicine and Science.

American Psychological Association (APA)

The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

Continuing Education Credits (CEUs)

Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

CME Committee Members

  • Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair
  • Catherine Friedman, MD, FASAM, Vice-Chair
  • Noel Ilogu, MD, MRCP, FASAM
  • Herbert L. Malinoff, MD, FACP, DFASAM
  • Edwin A. Salsitz, MD, DFASAM
  • John C. Tanner, DO, CCFC, DFASAM

Staff - Sandy Metcalfe, Consultant, ASAM CME Committee, Professional Development Department

CME Committee, Program Planning Committee and Faculty Disclosure Information

In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

Who Should Attend:

  • Physicians and Clinicians
  • Researchers and Academics
  • Counselors and Students
  • Other Health Care Professionals 

dedicated to increasing access and improving the quality of addiction treatment and care.